This company listing is no longer active
Bionomics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Bionomics's earnings have been declining at an average annual rate of -3.4%, while the Biotechs industry saw earnings growing at 16% annually. Revenues have been declining at an average rate of 42.6% per year.
Información clave
-3.4%
Tasa de crecimiento de los beneficios
27.8%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 9.6% |
| Tasa de crecimiento de los ingresos | -42.6% |
| Rentabilidad financiera | -52.2% |
| Margen neto | -413.9% |
| Última actualización de beneficios | 31 Dec 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?
Jun 14
Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?
Feb 23Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?
Sep 14Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth
Nov 15Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?
Dec 30Desglose de ingresos y gastos
Cómo gana y gasta dinero Bionomics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 22 | 6 | -25 | 7 | 0 |
| 30 Sep 22 | 6 | -23 | 7 | 0 |
| 30 Jun 22 | 6 | -22 | 8 | 0 |
| 31 Mar 22 | 3 | -22 | 8 | 0 |
| 31 Dec 21 | 0 | -22 | 8 | 0 |
| 30 Sep 21 | 1 | -15 | 7 | 0 |
| 30 Jun 21 | 1 | -9 | 6 | 0 |
| 31 Mar 21 | 1 | -4 | 5 | 0 |
| 31 Dec 20 | 2 | 1 | 5 | 0 |
| 30 Sep 20 | 2 | -3 | 5 | 0 |
| 30 Jun 20 | 3 | -6 | 5 | 0 |
| 31 Dec 19 | 6 | -5 | 5 | 0 |
| 30 Sep 19 | 7 | -8 | 6 | 0 |
| 30 Jun 19 | 7 | -10 | 8 | 0 |
| 31 Mar 19 | 8 | -20 | 11 | 0 |
| 31 Dec 18 | 8 | -28 | 11 | 0 |
| 30 Sep 18 | 10 | -27 | 11 | 0 |
| 30 Jun 18 | 12 | -25 | 11 | 0 |
| 31 Mar 18 | 19 | -15 | 9 | 0 |
| 31 Dec 17 | 27 | -6 | 8 | 0 |
| 30 Sep 17 | 27 | -6 | 8 | 0 |
| 30 Jun 17 | 27 | -7 | 8 | 0 |
| 31 Mar 17 | 22 | -12 | 10 | 0 |
| 31 Dec 16 | 16 | -17 | 12 | 0 |
| 30 Sep 16 | 18 | -17 | 11 | 0 |
| 30 Jun 16 | 19 | -17 | 11 | 0 |
| 31 Mar 16 | 19 | -19 | 10 | 0 |
| 31 Dec 15 | 18 | -21 | 9 | 0 |
| 30 Sep 15 | 17 | -19 | 9 | 0 |
| 30 Jun 15 | 15 | -17 | 9 | 0 |
| 31 Mar 15 | 22 | -6 | 7 | 0 |
| 31 Dec 14 | 29 | 4 | 5 | 0 |
| 30 Sep 14 | 28 | 4 | 5 | 0 |
| 30 Jun 14 | 27 | 3 | 5 | 0 |
| 31 Mar 14 | 19 | -5 | 5 | 0 |
| 31 Dec 13 | 12 | -13 | 5 | 0 |
| 30 Sep 13 | 12 | -11 | 5 | 0 |
| 30 Jun 13 | 12 | -10 | 5 | 0 |
| 31 Mar 13 | 13 | -7 | 5 | 0 |
| 31 Dec 12 | 13 | -4 | 4 | 0 |
| 30 Sep 12 | 12 | -3 | 4 | 0 |
Ingresos de calidad: BNO is currently unprofitable.
Margen de beneficios creciente: BNO is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: BNO is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.
Acelerando crecimiento: Unable to compare BNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: BNO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Rentabilidad financiera
Alta ROE: BNO has a negative Return on Equity (-52.21%), as it is currently unprofitable.